Strong Revenue Growth
Revenue from continuing operations was $13 million, an increase of 14% over the prior year period, driven by strong device sales.
Record Device Placements
Placed 164 devices in Q2, including a record number of XplorIR units, marking the highest quarterly performance for XplorIR.
Improvement in Adjusted EBITDA
Adjusted EBITDA loss was $3.9 million for the quarter, an improvement of more than 45% year-over-year and reduced by 15% quarter-over-quarter.
Legislative Support and Funding Increases
Recent U.S. legislative actions, like the One Big Beautiful Bill, increased funding for law enforcement and security initiatives, providing a favorable environment for device sales.
Launch of VipIR
Successful launch of VipIR, a new 3-in-1 handheld chemical analyzer, designed for high-stakes environments, enhancing the product portfolio.
Operational Efficiency Improvements
Completed transfer of MX908 manufacturing to a lower-cost facility and acquisition of KAF Manufacturing to enhance supply chain and margin improvement.